Becton, Dickinson and Company (BD) has announced the global distribution of a complete portfolio of products for mass spectrometry that provides high-speed and high-confidence identification of pathogens in clinical laboratories—a critical first step in the fight against antimicrobial resistance.
Current trends project antimicrobial resistance could cause up to 10 million deaths annually by 2050. Fast and accurate identification of pathogens is often the first step in addressing this issue. BD is offering MBT Biotargets and MBT Sepsityper, as well as standard reagents and other products, which completes a comprehensive mass spectrometry solution based on Bruker’s MALDI Biotyper time-of-flight mass spectrometer. MBT Biotargets are disposable plates that can be run multiple times, reducing waste. MBT Sepsityper, a new sepsis management kit, enables pathogen identification from positive blood cultures, eliminating the need to culture the micro-organisms.
BD’s complete portfolio offer of MALDI Biotyper products including the MALDI Biotyper smart, an enhanced version of the BD Bruker MALDI Biotyper allows health care providers to accurately and more effectively assist in diagnosing patients with infectious diseases in minutes. The seamless connectivity between the BD Bruker MALDI Biotyper connects to the recently launched BD Phoenix M50 and the BD EpiCenter data management system.
